Shots:

• Pharming to pay €7.5M in two tranches to Sobi and will reacquire exclusive rights to commercialize Ruconest in all remaining territories- which includes all remaining 36 EU markets and will be effective from Jan 1- 2020
• Pharming to cooperate with Sobi for the replacement of all contracts for distribution and other services as quickly as possible- and to transfer existing reimbursement approvals where possible
• Ruconest (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema in EU- the US- Israel- and South Korea

Click here to­ read full press release/ article | Ref: Pharming | Image: Twitter